⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
URGN News
UroGen Pharma Ltd. Ordinary Shares
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
globenewswire.com
URGN
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
globenewswire.com
URGN
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
globenewswire.com
URGN
The Galien Foundation Announces Nominees for the Inaugural 2026 Prix Galien Patient First Award in Honor of Michael J. Fox
prnewswire.com
AGIO
AZN
AMGN
ARDX
BDX
BMY
CGON
FERG
GILD
JNJ
UTHR
MRK
NVS
PFE
PRM
IQV
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
globenewswire.com
URGN
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
prnewswire.com
URGN
Form 8-K
sec.gov
URGN
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
globenewswire.com
URGN
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
globenewswire.com
URGN